Showing 1101-1110 of 1635 results for "".
- ThromboGenics Plans Name Change to “Oxurion”https://modernod.com/news/thrombogenics-plans-name-change-to-oxurion/2480064/ThromboGenics announced its intention to change its name to “Oxurion” and the company’s stock ticker symbol from ‘THR” to “OXUR.” The company issued a convening notice seeking the approval of ThromboGenics’ shareholders for the name change at an Extraordinary Genera
- Aerpio Pharmaceuticals Announces Uplisting to Nasdaq Capital Market and Pricing of $45 Million Public Offering of Common Stockhttps://modernod.com/news/aerpio-pharmaceuticals-announces-uplisting-to-nasdaq-capital-market-and-pricing-of-45-million-public-offering-of-common-stock/2480066/Aerpio Pharmaceuticals announced that its common stock will begin trading on the Nasdaq Capital Market under the symbol “ARPO” at the opening of trading on June 26, 2018, following its previously announced approval to list its common stock on the Nasdaq Capital Market. Aerpio also announce
- Silicon Valley Eye Doctor Named Optometrist of the Year By American Optometric Associationhttps://modernod.com/news/silicon-valley-eye-doctor-named-optometrist-of-the-year-by-american-optometric-association/2480071/The California Optometric Association (COA) announced that David M. Redman, OD, has been named the “Optometrist of the Year” for 2017 by the American Optometric Association (AOA). Dr. Redman is a practicing optometrist and partner in Precision Eyecare Centers in San Jose and Mountain View. Dr. Re
- ThromboGenics Partners with Prevent Blindness at 2018 Focus on Eye Health National Summit in Washington DChttps://modernod.com/news/thrombogenics-partners-with-prevent-blindness-at-2018-focus-on-eye-health-national-summit-in-washington-dc/2480077/ThromboGenics announced its participation and support of the seventh annual Prevent Blindness Focus on Eye Health National Summit which takes place on July 18, 2018, at the National Press Club in Washington, DC. The Focus on Eye Health National Summit aims to facilitate dialogue around vi
- Foundation Fighting Blindness Launches the Stargardt Disease Natural History Studyhttps://modernod.com/news/foundation-fighting-blindness-launches-the-stargardt-disease-natural-history-study/2480086/More than 60 leading retinal disease clinical researchers from around the world gathered in Baltimore on June 11, 2018 to discuss findings from ProgStar, the Stargardt disease natural history study launched by the Foundation Fighting
- OD-OS Introduces the Navilas expertLibrary Forum for Retina Specialistshttps://modernod.com/news/od-os-introduces-the-navilas-expertlibrary-forum-for-retina-specialists/2480093/OD-OS has introduced a new forum for retina specialists – the Navilas expertLibrary. The Navilas expertLibrary is an exclusive forum where leading retinal physicians share their day-to-day experience with this novel navigated retinal laser technology, according to OD-OS. Interested parties
- OD-OS Releases Software Update For the Computer-Guided Navilas 577s Laser Systemhttps://modernod.com/news/od-os-releases-software-update-for-the-computer-guided-navilas-577s-laser-system/2480112/OD-OS has released a comprehensive software update for the computer-guided Navilas 577s Laser System. New functionalities of software release 3.4 make the tissue-friendly treatment of retinal diseases using navigated microsecond laser pulses more intuitive, predictable, and reproducible, accordin
- Ocugen Presents Preclinical Efficacy Data of its Proprietary Nanoemulsion Technology at ARVO 2018https://modernod.com/news/ocugen-presents-preclinical-efficacy-data-of-its-proprietary-nanoemulsion-technology-at-arvo-2018/2480184/Ocugen announced that it presented additional preclinical findings in a poster highlighting the potential efficacy of its unique, patented nanoemulsion formulation of brimonidine tartrate (OCU300) at the Association for Research in Vision and Ophthalmology (ARVO) 2018 Annual Meeting, held
- Omidria Added to Veterans Health Administration National Formularyhttps://modernod.com/news/omidria-added-to-veterans-health-administration-national-formulary/2480248/Omeros announced that the Veterans Administration (VA) has added Omidria (phenylephrine and ketorolac intraocular solution 1% / 0.3%) to the VA National Formulary. The VA National Formulary is a listing of drugs and supplies that must be available at all VA facilities for the benefit of U.
- Ophthalmic World Leaders (OWL) Names First MD President and Other Leadership Changes for 2026https://modernod.com/news/ophthalmic-world-leaders-owl-names-first-md-president-and-other-leadership-changes-for-2026/2484293/Ophthalmic World Leaders (OWL) announces the appointment of Renee Bovelle, MD, as its new President. OWL also welcomes three new members to its Board of Directors: Kevin M. Douglas, MD (Medical Director, Eye Care – Retina, AbbVie), Maáza Martin (S